Androgen Deprivation Therapy clinical trials

Explore recruiting androgen deprivation therapy clinical trials.

Recruiting androgen deprivation therapy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Androgen Deprivation Therapy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial FinnProstata XV. ESTO2.

Denmark, Finland, Norway, Estonia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prostate-only, dose-escalated radiotherapy plus concomitant androgen deprivation therapy in primary localized, NCCN high risk and MMAI classifier low or intermediate-risk prostate cancer – a prospective, single-arm, phase II study

Cyprus

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

ADOPT; Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormonesensitive Prostate Cancer (mHSPC)

Czechia, Spain, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer

Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

Androgen Deprivation Therapy trials by city

Androgen Deprivation Therapy in Toronto Androgen Deprivation Therapy in Vancouver Androgen Deprivation Therapy in Montreal Androgen Deprivation Therapy in Calgary Androgen Deprivation Therapy in Edmonton Androgen Deprivation Therapy in Ottawa Androgen Deprivation Therapy in Winnipeg Androgen Deprivation Therapy in Quebec City Androgen Deprivation Therapy in Hamilton Androgen Deprivation Therapy in Kitchener Androgen Deprivation Therapy in London Androgen Deprivation Therapy in Halifax Androgen Deprivation Therapy in New York Androgen Deprivation Therapy in Los Angeles Androgen Deprivation Therapy in Chicago Androgen Deprivation Therapy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease